Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables - Other (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Receivables - Other data on record, last reported at $100000.0 in Q4 2025.

  • For Q4 2025, Receivables - Other changed 0.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $100000.0, changed 0.0%, while the annual FY2025 figure was $100000.0, 0.0% changed from the prior year.
  • Receivables - Other reached $100000.0 in Q4 2025 per AMLX's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $800000.0 in Q2 2023 and bottomed at $100000.0 in Q3 2023.
  • Average Receivables - Other over 4 years is $246153.8, with a median of $100000.0 recorded in 2023.
  • Peak YoY movement for Receivables - Other: changed 0.0% in 2023, then crashed 87.5% in 2024.
  • A 4-year view of Receivables - Other shows it stood at $500000.0 in 2022, then changed by 0.0% to $500000.0 in 2023, then tumbled by 80.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $100000.0 in Q4 2025, $100000.0 in Q3 2025, and $100000.0 in Q2 2025.